Literature DB >> 16545727

Inflammatory cytokines and the development of pulmonary complications after allogeneic hematopoietic cell transplantation in patients with inherited metabolic storage disorders.

Sandhya Kharbanda1, Angela Panoskaltsis-Mortari, Imad Y Haddad, Bruce R Blazar, Paul J Orchard, David N Cornfield, Satkiran S Grewal, Charles Peters, Warren E Regelmann, Carlos E Milla, K Scott Baker.   

Abstract

Patients with inherited metabolic storage disorders are at a higher risk of developing pulmonary complications after hematopoietic cell transplantation (HCT). This single-center prospective study of 48 consecutive inherited metabolic storage disorder patients was performed to identify risk factors for the development of pulmonary complications after HCT. Before HCT, subjects underwent bronchoalveolar lavage (BAL) for cell count, culture, nitrite levels, and analysis of proinflammatory cytokines and chemokines. The overall incidence of pulmonary complications was 52% (infectious, 23%; noninfectious, 29%) over a period of 4 years. Diffuse alveolar hemorrhage was the most frequent noninfectious complication and occurred in 19% of patients, all of whom had a diagnosis of mucopolysaccharidosis (Hurler and Maroteaux-Lamy syndromes). Levels of interleukin (IL)-1beta, IL-6, IL-8, tumor necrosis factor alpha, macrophage inflammatory protein 1alpha, and granulocyte colony-stimulating factor in BAL fluid samples obtained before HCT were higher in patients with mucopolysaccharidoses than in patients with leukodystrophies. In addition, levels of IL-1beta, IL-6, IL-8, and granulocyte colony-stimulating factor were increased in the BAL fluid of patients who developed noninfectious pulmonary complications compared with those who did not develop pulmonary complications. It is interesting to note that most noninfectious pulmonary complications occurred in patients with mucopolysaccharidoses, especially diffuse alveolar hemorrhage, which occurred exclusively in patients with mucopolysaccharidoses. Higher levels of bronchial proinflammatory cytokines and chemokines may be predictive of the development of subsequent posttransplantation noninfectious complications in patients with mucopolysaccharidoses, especially those with Hurler syndrome. Larger studies will be required to further elucidate etiologic mechanisms and predictive factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545727     DOI: 10.1016/j.bbmt.2005.12.026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  12 in total

1.  The effects of early and late bone marrow transplantation in siblings with alpha-mannosidosis. Is early haematopoietic cell transplantation the preferred treatment option?

Authors:  A A Broomfield; A Chakrapani; J E Wraith
Journal:  J Inherit Metab Dis       Date:  2010-02-18       Impact factor: 4.982

Review 2.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

3.  Long-term functional outcomes of children with hurler syndrome treated with unrelated umbilical cord blood transplantation.

Authors:  Hannah Y Coletti; Mieke Aldenhoven; Karina Yelin; Michele D Poe; Joanne Kurtzberg; Maria L Escolar
Journal:  JIMD Rep       Date:  2015-01-23

4.  Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates.

Authors:  Matt S Zinter; A Birgitta Versluys; Caroline A Lindemans; Madeline Y Mayday; Gustavo Reyes; Sara Sunshine; Marilynn Chan; Elizabeth K Fiorino; Maria Cancio; Sabine Prevaes; Marina Sirota; Michael A Matthay; Sandhya Kharbanda; Christopher C Dvorak; Jaap J Boelens; Joseph L DeRisi
Journal:  Sci Transl Med       Date:  2022-03-09       Impact factor: 19.319

5.  Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Sagar S Patel; Kwang Woo Ahn; Manoj Khanal; Caitrin Bupp; Mariam Allbee-Johnson; Navneet S Majhail; Betty K Hamilton; Seth J Rotz; Hasan Hashem; Amer Beitinjaneh; Hillard M Lazarus; Maxwell M Krem; Tim Prestidge; Neel S Bhatt; Akshay Sharma; Shahinaz M Gadalla; Hemant S Murthy; Larisa Broglie; Taiga Nishihori; César O Freytes; Gerhard C Hildebrandt; Usama Gergis; Sachiko Seo; Baldeep Wirk; Marcelo C Pasquini; Bipin N Savani; Mohamed L Sorror; Edward A Stadtmauer; Saurabh Chhabra
Journal:  Transplant Cell Ther       Date:  2022-03-18

Review 6.  Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Authors:  Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida
Journal:  J Inherit Metab Dis       Date:  2018-02-01       Impact factor: 4.982

7.  Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.

Authors:  Robert F Tamburro; Kenneth R Cooke; Stella M Davies; Samuel Goldfarb; James S Hagood; Ashok Srinivasan; Marie E Steiner; Dennis Stokes; Nancy DiFronzo; Nahed El-Kassar; Nonniekaye Shelburne; Aruna Natarajan
Journal:  Ann Am Thorac Soc       Date:  2021-03

8.  The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury.

Authors:  Matt S Zinter; Caroline A Lindemans; Birgitta A Versluys; Madeline Y Mayday; Sara Sunshine; Gustavo Reyes; Marina Sirota; Anil Sapru; Michael A Matthay; Sandhya Kharbanda; Christopher C Dvorak; Jaap J Boelens; Joseph L DeRisi
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

Review 9.  Interstitial Lung Disease in Childhood: Clinical and Genetic Aspects.

Authors:  Hiroshi Kitazawa; Shigeo Kure
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-10-11

Review 10.  Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation.

Authors:  Güldane Cengiz Seval; Pervin Topçuoğlu; Taner Demirer
Journal:  Balkan Med J       Date:  2018-03-15       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.